These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 15301704)

  • 41. RB1 polymorphism contributes to the efficacy of platinum-taxanes in advanced squamous cell lung cancer.
    Liu D; Xu W; Zhang ZW; Qian J; Zheng H; Zhang J; Su B
    Asian Pac J Cancer Prev; 2015; 16(2):775-81. PubMed ID: 25684524
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A retrospective comparison of adjuvant chemotherapeutic regimens for non-small cell lung cancer (NSCLC): paclitaxel plus carboplatin versus vinorelbine plus cisplatin.
    Chang WJ; Sun JM; Lee JY; Ahn JS; Ahn MJ; Park K
    Lung Cancer; 2014 Apr; 84(1):51-5. PubMed ID: 24521819
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of expression and polymorphism of the BAG-1 gene in response to platinum-based chemotherapeutics in NSCLC.
    Wang YD; Ha MW; Cheng J; Zhang WL; Cong X; Tong CY; Sun J
    Oncol Rep; 2012 Apr; 27(4):979-86. PubMed ID: 22179630
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chemotherapy-induced neutropenia does not correlate with DNA repair gene polymorphisms and treatment efficacy in advanced non-small-cell lung cancer patients.
    Iranzo V; Sirera R; Bremnes RM; Blasco A; Jantus-Lewintre E; Tarón M; Berrocal A; Blasco S; Caballero C; Del Pozo N; Rosell R; Camps C
    Clin Lung Cancer; 2011 Jul; 12(4):224-30. PubMed ID: 21726821
    [TBL] [Abstract][Full Text] [Related]  

  • 45. MDR1 single nucleotide polymorphisms predict response to vinorelbine-based chemotherapy in patients with non-small cell lung cancer.
    Pan JH; Han JX; Wu JM; Sheng LJ; Huang HN; Yu QZ
    Respiration; 2008; 75(4):380-5. PubMed ID: 17851225
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine.
    Viñolas N; Provencio M; Reguart N; Cardenal F; Alberola V; Sánchez-Torres JM; Barón FJ; Cobo M; Maestu I; Moreno I; Mesía C; Izquierdo A; Felip E; López-Brea M; Márquez A; Sánchez-Ronco M; Tarón M; Santarpia MC; Rosell R;
    Lung Cancer; 2011 Feb; 71(2):191-8. PubMed ID: 20627363
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Association of DNA repair gene polymorphisms with response to platinum-based doublet chemotherapy in patients with non-small-cell lung cancer.
    Shiraishi K; Kohno T; Tanai C; Goto Y; Kuchiba A; Yamamoto S; Tsuta K; Nokihara H; Yamamoto N; Sekine I; Ohe Y; Tamura T; Yokota J; Kunitoh H
    J Clin Oncol; 2010 Nov; 28(33):4945-52. PubMed ID: 20940192
    [TBL] [Abstract][Full Text] [Related]  

  • 48. GSTP1 Ile105Val and XRCC1 Arg399Gln gene polymorphisms contribute to the clinical outcome of patients with advanced non-small cell lung cancer.
    Bu L; Zhang LB; Mao X; Wang P
    Genet Mol Res; 2016 Jun; 15(2):. PubMed ID: 27323109
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PTEN polymorphisms contribute to clinical outcomes of advanced lung adenocarcinoma patients treated with platinum-based chemotherapy.
    Yang Y; Xu W; Liu D; Ding X; Su B; Sun Y; Gao W
    Tumour Biol; 2016 Jun; 37(6):7785-96. PubMed ID: 26695147
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for Chinese non-small cell lung cancer patients.
    Wu W; Li H; Wang H; Zhao X; Gao Z; Qiao R; Zhang W; Qian J; Wang J; Chen H; Wei Q; Han B; Lu D
    PLoS One; 2012; 7(3):e33200. PubMed ID: 22479369
    [TBL] [Abstract][Full Text] [Related]  

  • 51. MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer.
    Sun N; Sun X; Chen B; Cheng H; Feng J; Cheng L; Lu Z
    Cancer Chemother Pharmacol; 2010 Feb; 65(3):437-46. PubMed ID: 19568750
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Association of GSTP1 and XRCC1 gene polymorphisms with clinical outcomes of patients with advanced non-small cell lung cancer.
    Liu JY; Liu QM; Li LR
    Genet Mol Res; 2015 Aug; 14(3):10331-7. PubMed ID: 26345972
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The relationship between polymorphisms of genes regulating DNA repair or cell division and the toxicity of platinum and vinorelbine chemotherapy in advanced NSCLC patients.
    Powrózek T; Mlak R; Krawczyk P; Homa I; Ciesielka M; Kozioł P; Prendecka M; Milanowski J; Małecka-Massalska T
    Clin Transl Oncol; 2016 Feb; 18(2):125-31. PubMed ID: 26193985
    [TBL] [Abstract][Full Text] [Related]  

  • 54. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer.
    Kalikaki A; Kanaki M; Vassalou H; Souglakos J; Voutsina A; Georgoulias V; Mavroudis D
    Clin Lung Cancer; 2009 Mar; 10(2):118-23. PubMed ID: 19362955
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Role of ERCC5 promoter polymorphisms in response to platinum-based chemotherapy in patients with advanced non-small-cell lung cancer.
    He C; Duan Z; Li P; Xu Q; Yuan Y
    Anticancer Drugs; 2013 Mar; 24(3):300-5. PubMed ID: 23211354
    [TBL] [Abstract][Full Text] [Related]  

  • 56. KRAS mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive value.
    Mellema WW; Dingemans AM; Thunnissen E; Snijders PJ; Derks J; Heideman DA; Van Suylen R; Smit EF
    J Thorac Oncol; 2013 Sep; 8(9):1190-5. PubMed ID: 23787801
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Retrospective analysis of second-line chemotherapy outcomes with paclitaxel or docetaxel in correlation with STMN1 polymorphism in advanced non-small cell lung cancer patients.
    Powrózek T; Mlak R; Krawczyk P; Bartoń S; Biernacka B; Małecka-Massalska T; Milanowski J
    Clin Transl Oncol; 2016 Jan; 18(1):33-9. PubMed ID: 26148901
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Genome-wide association study of myelosuppression in non-small-cell lung cancer patients with platinum-based chemotherapy.
    Cao S; Wang S; Ma H; Tang S; Sun C; Dai J; Wang C; Shu Y; Xu L; Yin R; Song X; Chen H; Han B; Li Q; Wu J; Bai C; Chen J; Jin G; Hu Z; Lu D; Shen H
    Pharmacogenomics J; 2016 Feb; 16(1):41-6. PubMed ID: 25823687
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The association of XRCC1 gene single nucleotide polymorphisms with response to neoadjuvant chemotherapy in locally advanced cervical carcinoma.
    Cheng XD; Lu WG; Ye F; Wan XY; Xie X
    J Exp Clin Cancer Res; 2009 Jun; 28(1):91. PubMed ID: 19563645
    [TBL] [Abstract][Full Text] [Related]  

  • 60. No association between XRCC1 polymorphisms and survival in non-small-cell lung cancer patients treated with platinum-based chemotherapy.
    Yuan P; Liu L; Wu C; Zhong R; Yu D; Wu J; Xu Y; Nie S; Miao X; Sun Y; Xu B; Lin D
    Cancer Biol Ther; 2010 Nov; 10(9):854-9. PubMed ID: 20814250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.